US OptionsDetailed Quotes
HUMA250117P4500
- 0.17
- +0.09+112.50%
15min DelayClose Jan 17 16:00 ET
0.20High0.05Low
0.10Open0.08Pre Close327 Volume1.54K Open Interest4.50Strike Price5.33KTurnover0.00%IV1.81%PremiumJan 17, 2025Expiry Date0.09Intrinsic Value100Multiplier-2DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma25.20Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Humacyte Stock Discussion
FDA delay in approving Humacyte stemmed from national security concerns - developed in collaboration with the DoD. An undeniable strategic advantage for the U.S. military.
The fact that we have a +10 billion $ runway is just nice to know.
Fresenius, with its stake and rights in Humacyte, could face a bidding war from Baxter, which seeks to expand its hemodialysis portfolio. Both see Humacyte’s innovative vascular technology as key to dominating the dialysis market.
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on watch for me, not an open po...
$Humacyte (HUMA.US)$
No comment yet